What is Curemark?
Curemark operates at the intersection of advanced biotechnology and neuro-pharmacology, focusing on the development of novel therapies for conditions such as autism, ADHD, addiction, schizophrenia, and Parkinson's disease. Through its wholly-owned subsidiary, Galenagen, the company extends its reach into antibacterial and antiviral treatments, as well as specialized medical devices. By leveraging a robust pipeline of preclinical and clinical-stage programs, Curemark maintains a competitive edge in the biopharma sector, prioritizing patient-centric outcomes and innovative molecular research to disrupt traditional treatment paradigms for complex brain-related disorders.
How much funding has Curemark raised?
Curemark has raised a total of $67.7M across 9 funding rounds:
Debt
$6M
Private Equity
$18.5M
Debt
$5M
Private Equity
$20.3M
Private Equity
$3M
Private Equity
$3.2M
Debt
$150K
Debt (2012): $6M, investors not publicly disclosed
Private Equity (2013): $18.5M, investors not publicly disclosed
Debt (2014): $5M, investors not publicly disclosed
Private Equity (2015): $20.3M, investors not publicly disclosed
Private Equity (2017): $3M, investors not publicly disclosed
Private Equity (2018): $3.2M, investors not publicly disclosed
Debt (2020): $150K featuring PPP
Key Investors in Curemark
PPP
Public-Private Partnership
Undisclosed Institutional Investor
A private equity firm focused on long-term capital appreciation within the life sciences and healthcare sectors.
Undisclosed Debt Provider
A specialized lending institution providing structured debt solutions to support clinical-stage biopharmaceutical development.
What's next for Curemark?
Looking ahead, Curemark is positioned to leverage its recent capital injection to accelerate its clinical-stage programs toward regulatory milestones. The strategic focus remains on transitioning its primary neurological candidates through the final phases of clinical validation. As the company scales its research infrastructure, it is likely to prioritize partnerships that enhance its therapeutic delivery mechanisms. By maintaining a disciplined approach to capital allocation, Curemark aims to translate its scientific breakthroughs into commercialized medical solutions, thereby securing its long-term viability in the highly competitive biopharmaceutical landscape.
See full Curemark company page
